DPYSL2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10772(DPYSL2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The DPYSL2 (Dihydropyrimidinase-like 2) antibody targets a protein encoded by the DPYSL2 gene, also known as CRMP2 (Collapsin Response Mediator Protein 2). This cytosolic phosphoprotein is highly expressed in the nervous system and plays critical roles in neurodevelopment, including axon guidance, neurite outgrowth, and neuronal migration by regulating microtubule dynamics. DPYSL2 interacts with signaling pathways such as Semaphorin and Slit, influencing cytoskeletal organization.

Antibodies against DPYSL2 are widely used in neuroscience research to study its function in neuronal differentiation, synaptic plasticity, and neurodegenerative disorders like Alzheimer’s disease, where abnormal phosphorylation of DPYSL2 is implicated. They are also employed in cancer research, as DPYSL2 overexpression or dysregulation has been linked to tumor progression and metastasis in certain cancers, including lung and breast cancer.

Commercial DPYSL2 antibodies are typically developed in hosts like rabbits or mice, validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence. Researchers must consider post-translational modifications (e.g., phosphorylation at specific residues) that may affect antibody specificity. Studies using these antibodies have contributed to understanding DPYSL2’s dual role as a potential biomarker and therapeutic target in neurological and oncological contexts.